Biogen

This study tests an approved drug for Friedreich's ataxia (called omaveloxolone or SKYCLARYS) in children aged 2 to 15. The goal is to see how the drug moves through their bodies and whether it is safe. About 33 children will take the drug in two parts, first a single dose and th…

This study looks at the long-term safety of a drug called litifilimab for adults with active systemic lupus erythematosus (SLE). Participants, who have already completed a previous study, will receive injections of litifilimab every 4 weeks for up to 156 weeks while continuing th…

This study tests the long-term safety of the drug litifilimab in adults with a type of lupus that affects the skin (cutaneous lupus). Participants have already completed a previous study and will receive injections every 4 weeks for up to 2 years (or 5 years in the US). Researche…

This study looks at whether a higher dose of nusinersen can improve arm and hand function in teenagers and adults with spinal muscular atrophy (SMA) who cannot walk and have already taken another SMA drug called risdiplam. Participants receive two high loading doses, then regular…

This study tests a new drug called litifilimab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 562 adults already on standard lupus treatments will receive either litifilimab or a placebo as a shot every 4 weeks for a year. The goal …

This study looks at the long-term safety of a higher dose of nusinersen (a drug for spinal muscular atrophy) in about 115 people who already completed a previous nusinersen study. Participants will receive the drug every 4 months via a lumbar puncture for up to 64 months, with fo…

This study tests an experimental drug called BIIB122 in 650 adults with early-stage Parkinson's disease. The goal is to see if BIIB122 can slow down the worsening of symptoms like movement problems and daily living challenges. Participants take a daily tablet for up to 3 years, a…

This phase 3 study tests whether the drug tofersen can delay or prevent the start of ALS in adults who carry a SOD1 gene mutation but do not yet have symptoms. The trial includes 158 participants and compares tofersen to a placebo. Researchers will measure how many people develop…

This study tests a new drug called litifilimab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 548 adults already on standard lupus treatments will receive either litifilimab or a placebo as a shot every 4 weeks for a year. The goal …

This study looks at the long-term safety of felzartamab in people who have had a kidney transplant and developed antibody-mediated rejection (AMR), where the immune system attacks the new kidney. Participants who completed an earlier study can receive felzartamab for up to 4 more…

This study tests an experimental drug called BIIB017 in children aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see if the drug can reduce the number of MS attacks (relapses) and is safe for long-term use. Participants will receive either BIIB017 o…

This study looks at how many people with multiple sclerosis (MS) develop antibodies against the drug natalizumab when it is given as a shot under the skin. Researchers will use data from European MS registries to track about 400 patients, including those new to the drug and those…

This study looks at the long-term safety of two MS drugs, Vumerity and Tecfidera, by analyzing data from over 10,500 patients in large registries. Researchers will track serious side effects like infections and cancer, comparing these drugs to other MS treatments. The goal is to …

This study is a nationwide registry in China that follows 600 children with spinal muscular atrophy (SMA). The goal is to understand how the disease progresses naturally and how well current treatments work in everyday life. Researchers will collect information from both past med…